News about Global Pharma

Panasonic and Shinobi Therapeutics to Develop iPS Cell Therapy Manufacturing Tech

Shinobi Therapeutics has joined hands with Panasonic Holdings Corp. and Kyoto University's Center for iPS Cell Research and Application (CiRA).

Global Pharma | 23/04/2024 | By Aishwarya |  204

PharmaLogic Opens New Radiopharmaceutical Production Facility in Cincinnati

PharmaLogic Holdings Corp. has opened its new radiopharmaceutical production and research facility in Cincinnati, Ohio.

Global Pharma | 23/04/2024 | By Aishwarya |  885

Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC

Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.

Global Pharma | 23/04/2024 | By Aishwarya |  353

Ipsen and Skyhawk Therapeutics to Work on RNA Targeting Research in Rare Neurological Diseases

Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

Global Pharma | 22/04/2024 | By Aishwarya |  468

Essential Pharma Acquires Reminyl Oral Capsules

Essential Pharma has completed the acquisition of Reminyl oral capsules from Janssen Pharmaceutica NV.

Global Pharma | 22/04/2024 | By Aishwarya |  307

SIIPL Signs Licensing Agreement with University of Oxford for Meningitis-B Vaccine

Serum Institute of India Pvt. Ltd. (SIIPL) and the University of Oxford have formalised a Licence of Technology Agreement negotiated by Oxford University Innovation in a significant stride towards addressing the challenge of Men-B disease.

Global Pharma | 22/04/2024 | By Aishwarya |  670

Genentech Receives Approval from FDA for Alecensa

Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Global Pharma | 22/04/2024 | By Aishwarya |  700

CordenPharma, GENEPEP Celebrate Strong Alliance for Developing Peptide Drug Substance

CordenPharma and GENEPEP have recently celebrated one year of their fruitful collaboration.

Global Pharma | 20/04/2024 | By Aishwarya |  529

FDA Approves GenFleet's GFH925 Phase III Trial for Colorectal Cancer

The primary objective is to compare the efficacy of GFH925 versus the current standard of care.

Global Pharma | 20/04/2024 | By Abha |  762

Nora Pharma Gets Health Canada Approval for Commercializing NIOPEG

Nora Pharma has received approval for its first Biosimilar product.

Global Pharma | 20/04/2024 | By Aishwarya |  885